Vir Biotechnology Q4 revenue beats estimates

Reuters

13 hours ago

<a href="https://laohu8.com/S/VIR">Vir Biotechnology</a> Q4 revenue beats estimates

Overview

Biopharmaceutical firm's Q4 revenue beat analyst expectations, driven by Norgine license revenue
Company reported a net loss for Q4, decreased compared to last year
Company announced collaboration with Astellas for prostate cancer treatment development

Outlook

Vir expects cash reserves to fund operations into Q2 2028

Result Drivers

NORGINE LICENSE REVENUE - Q4 revenue increase driven by $64.3 mln license revenue from Norgine agreement for hepatitis delta treatment
COST SAVINGS - Decrease in R&D and SG&A expenses due to cost savings from restructuring initiatives

Company press release: ID:nBwbtQvVSa

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue	Beat	$64.10 mln	$23.18 mln (6 Analysts)
Q4 EPS		-$0.31
Q4 Net Income		-$42.9 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Vir Biotechnology Inc is $14.50, about 95.2% above its February 23 closing price of $7.43

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2613753694"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2613753694\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2613753694?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 06:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613753694","market":"fut","top_or_hot":-1,"title":"Vir Biotechnology Q4 revenue beats estimates","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> Q4 revenue beats estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Biopharmaceutical firm's Q4 revenue beat analyst expectations, driven by Norgine license revenue</p></li><li><p>Company reported a net loss for Q4, decreased compared to last year</p></li><li><p>Company announced collaboration with Astellas for prostate cancer treatment development</p></li></ul><p><span>Outlook</span></p><ul><li><p>Vir expects cash reserves to fund operations into <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2028</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>NORGINE LICENSE REVENUE - Q4 revenue increase driven by $64.3 mln license revenue from Norgine agreement for hepatitis delta treatment</p></li><li><p>COST SAVINGS - Decrease in R&amp;D and SG&amp;A expenses due to cost savings from restructuring initiatives</p></li></ul><p>Company press release: <span>ID:nBwbtQvVSa</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>$64.10 mln</p></td><td><p>$23.18 mln (6 Analysts)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$0.31</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$42.9 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Vir Biotechnology Inc is $14.50, about 95.2% above its February 23 closing price of $7.43</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vir Biotechnology Q4 revenue beats estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir Biotechnology Q4 revenue beats estimates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-24 06:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> Q4 revenue beats estimates</title></head><body><p><span>Overview</span></p><ul><li><p>Biopharmaceutical firm's Q4 revenue beat analyst expectations, driven by Norgine license revenue</p></li><li><p>Company reported a net loss for Q4, decreased compared to last year</p></li><li><p>Company announced collaboration with Astellas for prostate cancer treatment development</p></li></ul><p><span>Outlook</span></p><ul><li><p>Vir expects cash reserves to fund operations into <a href=\"https://laohu8.com/S/QTWO\">Q2</a> 2028</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>NORGINE LICENSE REVENUE - Q4 revenue increase driven by $64.3 mln license revenue from Norgine agreement for hepatitis delta treatment</p></li><li><p>COST SAVINGS - Decrease in R&amp;D and SG&amp;A expenses due to cost savings from restructuring initiatives</p></li></ul><p>Company press release: <span>ID:nBwbtQvVSa</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Beat</p></td><td><p>$64.10 mln</p></td><td><p>$23.18 mln (6 Analysts)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-$0.31</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>-$42.9 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Vir Biotechnology Inc is $14.50, about 95.2% above its February 23 closing price of $7.43</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL1N3ZJ159:1","article_id":"2613753694","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613753694","pubTimestamp":1771885387,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vir Biotechnology Q4 revenue beats estimatesOverviewBiopharmaceutical firm's Q4 revenue beat analyst expectations, driven by Norgine license revenueCompany reported a net loss for Q4, decreased compar","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","VIR":"Vir Biotechnology, Inc.","BK4535":"淡马锡持仓","BK4139":"生物科技","BK4568":"美国抗疫概念"},"translate_title":"Vir Biotechnology第四季度收入超出预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIR":0.9},"content_text":"Vir Biotechnology Q4 revenue beats estimatesOverviewBiopharmaceutical firm's Q4 revenue beat analyst expectations, driven by Norgine license revenueCompany reported a net loss for Q4, decreased compared to last yearCompany announced collaboration with Astellas for prostate cancer treatment developmentOutlookVir expects cash reserves to fund operations into Q2 2028Result DriversNORGINE LICENSE REVENUE - Q4 revenue increase driven by $64.3 mln license revenue from Norgine agreement for hepatitis delta treatmentCOST SAVINGS - Decrease in R&D and SG&A expenses due to cost savings from restructuring initiativesCompany press release: ID:nBwbtQvVSaKey DetailsMetricBeat/MissActualConsensus EstimateQ4 RevenueBeat$64.10 mln$23.18 mln (6 Analysts)Q4 EPS-$0.31Q4 Net Income-$42.9 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 10 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Vir Biotechnology Inc is $14.50, about 95.2% above its February 23 closing price of $7.43For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}